sector medic suppli devic
ew mix tavr miss focu
alreadi anticip low-risk
messag ew result mix overal top bottom line beat
somewhat off-set anoth tavr miss expect investor look
shortfal anticip growth inflect follow low-risk label expans
ew share trade signific premium lc med-tech group ntm ep
vs believ meaning revenu upsid necessari point soon
support stock valuat view remain consensu tavr
growth model right set poor risk/reward current level
edward tavr busi disappoint global sale cc
came consensu mark fifth consecut quarter tavr revenu
light street expect albeit without dramat shortfal stretch
estim tavr revenu came roughli shi
street meanwhil peg intern sale cc consensu
edward estim ww tavr volum grew low double-digit clip quarter
price held stabl although hold line price cost compani share
europ dynam appear stabil past coupl
quarter ou launch sapien ultra centera underway edward
hope rebuild momentum move launch sapien ultra
could strengthen edward hand domest well expect incumb lose
ground enter fray lotu receiv fda approv last night call
manag reiter organ sale growth suggest backend load
investor focu shift away toward pace low risk adoption/
penetr see neg risk/reward stock low risk tavr result
present march repres best-cas scenario view tavr demonstr
clinic superior savr edward studi see result
behind us focu shift impact low risk label expans tavr
market growth bull anticip sharper inflect alreadi reflect
street estim model assum penetr low risk popul
view rel aggress forecast yet estim
edward tavr sale roughli line consensu period suggest
steeper adopt curv greater anticip increas diagnoses/referr
would necessari drive upsid number
turn back quarter upsid surgic heart valv therapi critic
off-set tavr shortfal shvt revenu rose cc ahead
consensu despit on-going tavr encroach edward continu enjoy solid savr
growth thank lead product portfolio posit mix driven adopt
higher price inspiri resilia valv believ ramp tavr adopt
eventu appli signific pressur edward surgic valv busi remain
impress compani abil leverag innov stay ahead wave
meanwhil often-overlook critic busi surpris upsid
revenu cc come ahead consensu
strength larg driven edward hemospher platform continu
build momentum compani roll acumen hypotens predict hpi
softwar final transcathet mitral tricupsid therapi tmtt revenu
top consensu driven initi pascal sale europ remind
initi litig edward europ alleg pascal infring
mitraclip patent proceed add extra degre uncertainti
near-term tmtt ramp edward continu target full year revenu
page analyst certif import disclosur
incom statement strong margin lower expect tax rate drove
bottom line beat edward report gross margin yoy
consensu sg spend rose yoy sale came
street expect expens increas yoy
sale in-lin consensu combin drove ebita margin
yoy higher street project final edward tax rate came
vs street expect ad anoth earn
pipelin front busi year edward tmtt portfolio
manag still work implic coapt design activ
cardioband pivot trial remain hold enrol clasp
pivot trial pascal on-going clasp studi function mr patient
expect begin later year look initi data pascal ce mark trial
medic meet next month earli indic product rel
competit vs mitraclip expect exceed world-wide sale
year ou edward also plan initi pivot trial transcathet
tricuspid repair although sever platform cardioband pascal
forma choos move forward depend result earli feasibl
studi current underway final pivot trial transcathet mitral valv
replac platform also slate kick later year
adjust estim model call adjust ep
total revenu cc compar prior estim
respect ew share trade revis ntm ep estim vs
large-cap med-tech averag see better opportun elsewher group
maintain neutral rate
page analyst certif import disclosur
edward one great med-tech success stori past decad
transform way valvular heart diseas treat process estim
world-wide tavr sale came cc edward busi
gener revenu cc work suggest tavr market
track reach sale next four year edward pois primari
beneficiari growth even competit increas howev street
expect acceler tavr market growth post low-risk label expans
alreadi high stock trade signific premium peer ntm ep vs
dont see risk/reward attract current level
edward share trade ntm ep estim ntm ebitda well
large-cap med-tech averag respect believ
edward best-in-class top-lin growth profil warrant premium valuat also make
compani difficult valu base tradit metric result employ
discount cash flow methodolog deriv fair valu estim assum
wacc termin growth rate calcul forward npv per
share equat multipl forward ntm ep estim
better upsid opportun elsewher group view remain neutral rate
upsid risk rate fair valu estim includ tavr market growth
exce street expect edward defend leadership posit world-wide
tavr share better forecast tmvr pipelin provid compani
meaning new growth driver sooner anticip
downsid risk rate fair valu estim includ tavr market growth
fall short street expect greater-than-expect share gain new tavr
competitor come market clinic and/or regulatori setback pipelin
program caus investor question sustain edward premium growth
page analyst certif import disclosur
million usd except
good sold
compani report guggenheim secur llc estim
page analyst certif import disclosur
million usd
compani report guggenheim secur llc estim
page analyst certif import disclosur
